Sorafenib

본문 바로가기


Home > Product > Sorafenib
Selling leads
Sorafenib
Posting date : Jun 30, 2025
Membership
Free Member Scince Jun 27, 2025
FOB Price
detailed discussion
Min. Order Quantity
1
Supply Abillity
hundreds of kgs
Port
Shanghai Port
Payment Terms
detailed discussion
Package
Convenient package
Keyword :
Category
Contact
Lena
Selling Leads Detail
Company Info
 
Quick Detail
Place of Origin
China [CN]
Brand Name
Royal
Model Number
+86 15242851296
HS-CODE
-
Package & Delivery Lead Time
Package
Convenient package
Detailed Description

Sorafenib (trade name Dorgime) is a new drug of molecular targeted therapy. It is an oral multi-target and multi-kinase inhibitor that can target serine/threonine kinases and receptor tyrosine kinases on tumor cells and tumor blood vessels. Sorafenib, on the one hand, can inhibit the receptor tyrosine kinases KIT and FLT-3 as well as the serine/threonine kinases in the Raf/MEK/ERK pathway in the Chemicalbook, significantly inhibiting the proliferation of tumor cells. On the other hand, by inhibiting the receptor tyrosine kinases VEGFR and PDG-FR upstream and the serine/threonine kinases in the Raf/MEK/ERK pathway downstream, tumor angiogenesis is significantly inhibited. That is to say, it can achieve two goals with one stone and take two measures simultaneously, exerting the dual effects of anti-angiogenesis and anti-tumor cell proliferation at the same time.


ECROBOT CO., Ltd, Business Registration Number : 220-88-71747, CEO J.W.Park, TEL : +82-2-552-7676, E-mail : E-mail : Contact us
Address : (Hwanghwa B/D 11F, Yeoksam-dong)320, Gangnam-daero, Gangnam-gu, Seoul, South Korea
About Us Privacy Policy Terms of use Copyright © 2000-2026 ECROBOT.COM. All rights reserved.
Top